According to the findings of a study, for chronic urticaria management in children, Omalizumab was used as second-line treatment by 1.7% and third-line by 20.7% of respondents. In Europe, there are little and inconsistent data regarding the diagnosis and treatment of chronic urticaria in children (0–18 years old), despite the fact that this condition is well reported in adults.

Researchers sought to examine regional variations and gauge the degree to which pediatric urticaria guidelines from the European Academy of Allergology and Clinical Immunology/ Global Allergy and Asthma European Network/European Dermatology Forum/World Allergy Organization (EAACI/GA2LEN/EDF/WAO) were followed. Members of the EAACI pediatric section were given access to an online clinical survey by the EAACI Task Force for paediatric chronic urticaria. A total of 35 multiple-choice questions about current procedures at each centre were posed to the participants.

A total of 2,773 doctors received the survey. Notably, 358 (13.8%) of them answered the survey, mostly pediatricians (49.7%) and pediatric allergists (80%), representing 69 different countries. In comparison to Northern European nations, Southern European nations used much more routine tests for diagnosis (such as parasite investigation, allergological testing, and autoimmune testing).

Most responders (60.3%) chose a second-generation antihistamine as their primary line of treatment, with 64.8% of them increasing their dosage as a second line. Notably, 1.7% of respondents used Omalizumab as a second-line treatment, while 20.7% used it as a third-line therapy. When diagnosing chronic urticaria, the majority of clinicians (65%) adhere to the EAACI/WAO/GA2LEN/EDF recommendations; only 7.3% do not.

The American Academy of Allergy Asthma and Immunology (AAAAI) practise parameter (1.7%) or national guidelines (18.4%, mostly from Northern Europe), respectively, were followed by some practitioners. The EAACI/WAO/GA2LEN/EDF guidelines are known to the majority of members of the Pediatric Section of EAACI, although a sizable portion of them do not adhere to them. The necessity for re-assessing, updating, and standardizing guidelines on the diagnosis and management of chronic urticaria in children is further strengthened by the wide diversity in diagnosis and therapy.